newsfilter
← Latest News
GlobeNewswire·

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with